ISO 10993 consists of 19 parts, each covering different aspects of biological evaluation of medical devices. Here are the subparts of ISO 10993:
- Part 1: Evaluation and Testing within a Risk Management Process
- Part 2: Animal Welfare Requirements
- Part 3: Tests for Genotoxicity, Carcinogenicity, and Reproductive Toxicity
- Part 4: Selection of Tests for Interactions with Blood
- Part 5: Tests for In Vitro Cytotoxicity
- Part 6: Tests for Local Effects after Implantation
- Part 7: Ethylene Oxide Sterilization Residuals
- Part 8: Selection and Qualification of Reference Materials for Biological Tests
- Part 9: Framework for Identification and Quantification of Potential Degradation Products
- Part 10: Tests for Irritation and Skin Sensitization
- Part 11: Tests for Systemic Toxicity
- Part 12: Sample Preparation and Reference Materials
- Part 13: Identification and Quantification of Degradation Products from Polymeric Medical Devices
- Part 14: Identification and Quantification of Degradation Products from Ceramics
- Part 15: Identification and Quantification of Degradation Products from Metals and Alloys
- Part 16: Toxicokinetic Study Design for Degradation Products and Leachables
- Part 17: Establishment of Allowable Limits for Leachable Substances
- Part 18: Chemical Characterization of Materials
- Part 19: Physico-Chemical, Morphological, and Topographical Characterization of Materials
Biocompatibility Requirement |
QA/QC Testing |
Validation Support |
Extracts/Material Characterization |
Cytotoxicity |
Bioburden |
GC/MS |
|
Sensitization |
AAMI/ISO Dose Audits |
Reusable Device |
LC/MS/MS |
Irritation |
Biological Indicator Tests |
Cleaning, Disinfection, and Sterilization Validation |
|
Systemic Toxicity |
Environmental Monitoring |
Accelerated Aging and Stability Testing |
|
Genotoxicity |
Bacterial Endotoxin (LAL) |
Package Integrity Testing |
AA, IR, GC, HPLC |
Implantation |
Microbiology/ Sterility Testing |
. |
Total Organic Carbon (TOC) |
Hemocompatibility |
. | . |
Organic Solvent Residues |
Surgical Models |
. | . |
Non-Volatile Residues |
Subchronic & ChronicToxicity |
. | . | . |
Carcinogenesis |
. | . | . |
PURPOSE OF BIOCOMPATIBILITY TESTING
Conducting Tests and Evaluating the Data
Introduction to Biocompatibility Testing
- the chemical and physical nature of its component materials
- the types of patient tissue that will be exposed to the device
- the duration of that exposure.
Applicability and Need of Biocompatibility Data
Biocompatibility data of one kind or another is almost always required for devices that have significant tissue contact. Below table describes the best to decide;
Device Categories |
Examples |
|
Surface
Device |
Skin |
Devices that
contact intact skin surfaces only. Examples include electrodes, external prostheses, fixation tapes, compression bandages and monitors of various types. |
Mucous membrane |
Devices communicating with
intact mucosal membranes. Examples
include contact lenses, urinary catheters, intravaginal and intraintestinal devices (stomach tubes,
sigmoidoscopes, colonoscopes, gastroscopes),
endotracheal tubes, bronchoscopes, dental
prostheses, orthodontic devices and IUD’s. |
|
Breached or compromised surfaces |
Devices that contact breached or
otherwise compromised external body
surfaces. Examples include ulcer, burn and granulation tissue dressings or healing devices and
occlusive patches. |
|
External Communicating Device |
Blood path indirect |
Devices that contact the blood path at one point and serve as a conduit for entry into the vascular system. Examples include solution administration sets, extension sets, transfer sets, and blood administration sets. |
Tissue/bone/dentin communicating |
Devices communicating with tissue, bone, and pulp/dentin system. Examples include laparoscopes, arthroscopes, draining systems, dental cements, dental filling materials and skin staples. This category also includes devices which contact internal tissues (rather than blood contact devices). Examples include many surgical instruments and accessories. |
|
Circulating blood |
Devices that contact circulating blood. Examples include intravascular catheters, temporary pacemaker electrodes, oxygenators, extracorporeal oxygenator tubing and accessories, hemoadsorbents and immunoabsorbents. |
|
Implant
Device |
Tissue/bone |
Devices
principally contacting bone. Examples include orthopedic pins, plates, replacement joints, bone prostheses, cements and intraosseous devices. Devices principally contacting tissue and
tissues fluid. Examples include
pacemakers, drug supply devices, neuromuscular sensors and stimulators, replacement tendons, breast
implants, artificial
larynxes,
subperiosteal implants and ligation clips. |
Blood |
Devices principally contacting blood. Examples include pacemaker electrodes, artificial arteriovenous fistulae, heart valves, vascular grafts and stents, internal drug delivery catheters, and ventricular assist devices. |
- Materials selection
- Manufacturing processes
- Chemical composition of materials
- Nature of patient contact
- Sterilization methods
Considerations for Biocompatibility Testing: Evaluating Device Materials and Finished Device Composites
- Assemble vendor data on candidate materials
- Conduct analytical and in vitro screening of materials
- Conduct confirmatory testing on a composite sample from the finished device
Biocompatibility Requirements
Requirement |
Test Name |
Cytotoxicity |
ISO Agar Overlay ISO MEM Elution ISO Direct Contact ISO MTT ISO Colony Formation |
Sensitization |
ASTM Murine Local Lymph Node Assay (LLNA) Maximization Test Closed Patch Test |
Irritation |
ISO Intracutaneous Test ISO Dermal Irritation ISO Ocular Irritation Mucous Membrane Irritation |
Systemic
Toxicity |
Material Mediated Pyrogen Test ISO Acute Systemic Test Subacute Subchronic Chronic |
Genotoxicity |
Ames Test Mouse Lymphoma Assay Mouse Micronucleus Assay Chromosomal Aberration Test |
Implantation |
Implantation Test (Local effects) (All ISO Implant Tests Include Histopathology) (7 days or greater) |
Hemocompatibility |
Hemolysis – ASTM Direct and Indirect Contact In Vivo Thrombogenicity In Vitro Platelet Aggregation Assay Partial Thromboplastin Time (PTT) Prothrombin Time (PT) Complement Activation |
Carcinogenesis |
L ifetime Toxicity |
Reproductive
and Developmental Toxicity |
Pharmacokinetic or ADME (Absorption/ Distribution/Metabolism/Excretion) |
Biodegradation |
Pharmacokinetic or ADME (Absorption/ Distribution/Metabolism/Excretion) |
Analytical
Test |
USP Physicochemical Tests Other Procedures |